beyond spring pharmaceuticals stock

3rd Party Ad. Price target decreased to US610.

Bysi Beyondspring Shares Crater After Fda Rejects Plinabulin Application R Bysi

BeyondSpring Inc NASDAQ Updated Oct 19 2022 800 PM.

. About BeyondSpring Pharmaceuticals Headquartered in New York City BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer. The Company is focused on developing cancer therapies to improve clinical outcomes for patients. Down from US1150 the current price target is an average from 4 analysts.

Is a clinical-stage global biopharmaceutical company. Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the US. PDUFA date of November.

20 2021 GLOBE NEWSWIRE -- BeyondSpring Pharmaceuticals the Company or BeyondSpring NASDAQ. New target price is 261 above last closing price of US169. And China for the prevention of CIN with a US.

NEW YORK Oct. BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte. Shares of BeyondSpring BYSI-004 a clinical-stage biotech company have been surging this week in response to a lucrative new partnership with Jiangsu.

BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from. Shares of BeyondSpring BYSI -717 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. Not an offer or recommendation by Stocktwits.

BYSI a global pharmaceutical company. Beyond Spring Pharmaceuticals BYSI Stock had a HUGE run today after it was announced they had data showing their treatment could potentially be the next bi. BYSI 080 006 707.

Mylan Investors Are Fed Up With Management And For Good Reason Analysts Say Fierce Pharma